Figure 7From: Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers Changes in plasma VEGF-A (ratio to baseline VEGF-A) according to clinical benefit during the first two treatment cycles and at the time of later progression (for patients that initially obtained a clinical benefit). CB: Clinical benefit; PD: Disease progressionBack to article page